Victor K. Outlaw

Victor K. Outlaw

Auto-generated profile, based on publicly available information

Victor K. Outlaw

University of Missouri

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 October 2020 in mBio
Verified
Journal Article
Open access
PDF file
VOVictor K. Outlaw
Victor K. Outlaw
FBFrancesca T. Bovier
Francesca T. Bovier
MMMegan C. Mears
Megan C. Mears
MCMaria N. Cajimat
Maria N. Cajimat
YZYun Zhu
Yun Zhu
MPMatteo Porotto
Matteo Porotto
SARS-CoV-2, the causative agent of COVID-19, continues to spread globally, placing strain on health care systems and resulting in rapidly increasing numbers of cases and mortalities. Despite the growing need for medical intervention, no FDA-approved vaccines are yet available, and treatment has been limited to supportive therapy for the alleviation of symptoms. Entry inhibitors could fill the important role of preventing initial infection and preventing spread. Here, we describe the design, synthesis, and evaluation of a lipopeptide that is derived from the HRC domain of the SARS-CoV-2 S glycoprotein that potently inhibits fusion mediated by SARS-CoV-2 S glycoprotein and blocks infection by live SARS-CoV-2 in both cell monolayers ( in vitro ) and human airway tissues ( ex vivo ). Our results highlight the SARS-CoV-2 HRC-derived lipopeptide as a promising therapeutic candidate for SARS-CoV-2 infections.

29 June 2021 in mBio
Verified
Journal Article
Open access
Cyrille MathieuCyrille Mathieu
Cyrille Mathieu
FBFrancesca T. Bovier
Francesca T. Bovier
MFMarion Ferren
Marion Ferren
NLNicole A. P. Lieberman
Nicole A. P. Lieberman
CPCamilla Predella
Camilla Predella
MPMatteo Porotto
Matteo Porotto
Measles virus (MeV) infection can cause serious complications in immunocompromised individuals, including measles inclusion body encephalitis (MIBE). In some cases, MeV persistence and subacute sclerosing panencephalitis (SSPE), another severe central nervous system (CNS) complication, develop even in the face of a systemic immune response.

3 July 2019 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
VOVictor K. Outlaw
Victor K. Outlaw
SBSamantha Bottom-Tanzer
Samantha Bottom-Tanzer
DKDale F. Kreitler
Dale F. Kreitler
SGSamuel H. Gellman
Samuel H. Gellman
MPMatteo Porotto
Matteo Porotto
AMAnne Moscona
Anne Moscona

7 April 2021 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
VOVictor K. Outlaw
Victor K. Outlaw
RCRoss Cheloha
Ross Cheloha
EJEric M. Jurgens
Eric M. Jurgens
FBFrancesca T. Bovier
Francesca T. Bovier
YZYun Zhu
Yun Zhu
AMAnne Moscona
Anne Moscona

17 January 2020 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
VOVictor K. Outlaw
Victor K. Outlaw
JLJennifer T. Lemke
Jennifer T. Lemke
YZYun Zhu
Yun Zhu
SGSamuel H. Gellman
Samuel H. Gellman
MPMatteo Porotto
Matteo Porotto
AMAnne Moscona
Anne Moscona

21 October 2025 in Chemical Science
Verified
Journal Article
Open access
PDF file
HSHassan Seyrani
Hassan Seyrani
HVHossein Heidarzadeh Vazifehkhorani
Hossein Heidarzadeh Vazifehkhorani
VOVictor K. Outlaw
Victor K. Outlaw
SuFEx-mediated tyrosine cyclization yields stable, bioactive macrocyclic peptides under mild aqueous conditions, expanding the toolbox for peptide drug discovery.